Effektivnost' antibakterial'noy terapii v kompleksnom lechenii yazvennogo kolita s proyavleniyami sindroma razdrazhennogo kishechnika


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The study was aimed to the evaluation of the efficacy of rifaximin-alpha in the treatment of patients with endoscopic remission of ulcerative colitis and the presence of symptoms similar to irritable bowel syndrome (IBS). The study included 37 patients with confirmed diagnosis of «ulcerative colitis». Quality of life was assessed by IBS-QOL questionnaire, and Beck’s questionnaire was used to assess the level of depression. All patients underwent feces analyses. As part of obligate microflora, number of bifidobacteria and lactobacilli using swab test method was estimated, as well as the presence of opportunistic pathogens of transient flora using dilution method and ELISA. After therapy with enterosoluble antibiotic rifaximin-alpha 800 mg per day for 9 days, incidence of IBS-like symptoms, quality of life and the composition of the luminal microflora of the colon were estimated. As a result of the therapy, marked improvement was noted: stool frequency decreased from 5.1 to 2.5 times a day; quality of life improved and levels of depression decreased; the frequency of complaints of IBS-like symptoms significantly decreased.

Full Text

Restricted Access

References

  1. Неспецифические воспалительные заболевания кишечника. Под ред. Г.И. Воробьева, И.Л. Халифа. М., 2008. 424 с.
  2. Stange E.F., Travis S.P.L., Vermeire S., et al. European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J. Crohns. Colitis. 2008,1(2):1-23.
  3. Barratt S.M., Leeds J.S., Robinson K., et al. Prodromal irritable bowel syndrome may be responsible for delays in diagnosis in patients presenting with unrecognized Crohn's disease and celiac disease, but not ulcerative colitis. Dig. Dis. Sci. 2011;56(11):3270-275.
  4. Keohane J., OMahony C., O'Mahony L., et al. Irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease: a real association or reflection of occult inflammation? Am. J. Gastroenterol. 2010;105(8):1788-94.
  5. Pullan R.D., Thomas G.A.O., Rhodes M., et al. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut. 1994;35:353-59.
  6. Corfield A.P., Myerscough N., Bradfield N., et al. Colonic mucins in ulcerative colitis: Evidence for loss of sulphation. Glycoconj. J. 1996; 13:809-22.
  7. Nishikawa J., Kudo T., Sakata S., et al. Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis. Scand. J. Gastroenterol. 2009;44:180-86.
  8. Kleessen B., Kroesen A.J., Buhr H.J., et al. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand. J. Gastroenterol. 2002;37:1034-41.
  9. Collins M.D., Lawson P.A., Willems A., et al. The phylogeny of the genus Clostridium: Proposal of five new genera and eleven new species combinations. Int. J. Syst. Bacteriol. 1994;44:812-26.
  10. Kotlowski R., Bernstein C.N., Sepehri S., et al. High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut. 2007;56:669-75.
  11. Rowan F.E., Docherty N.G., Coffey J.C., et al. Sulphate-reducing bacteria and hydrogen sulphide in the aetiology of ulcerative colitis. Br. J. Surg. 2009;96:151-58.
  12. Pitcher M.C., Beatty E.R., Cummings J.H. The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecalsulphide in patients with ulcerative colitis. Gut. 2000;46:64-72.
  13. Guslandi M. Antibiotics for inflammatory bowel disease: do they work? Eur. J. Gastroenterol. Hepatol. 2005;17:145-47.
  14. Rahimi R., Nikfar S., Rezaie A., et al. A metaanalysis of antibiotic therapy for active ulcerative colitis. Dig. Dis. Sci. 2007;52:2920-5.
  15. Koo H.L., DuPont H.L. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr. Opin. Gastroenterol. 2010; 26:17-25.
  16. Laustsen G., Wimmett L. 2004 drug approval highlights: FDA update. Nurse Pract. 2005;30:14-29; quiz 29-31.
  17. Day A.S., Gearry R.B. Rifaximin and Crohn's disease: a new solution to an old problem? Dig. Dis. Sci. 2010;55:877-79.
  18. Koo H.L., DuPont H.L. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr. Opin. Gastroentero. 2010; l26:17-25.
  19. Laustsen G., Wimmett L. 2004 drug approval highlights: FDA update. Nurse Pract. 2005;30:14-31.
  20. Day A.S., Gearry R.B. Rifaximin and Crohn's disease: a new solution to an old problem? Dig. Dis. Sci. 2010;55:877-79.
  21. Ардатская М.Д., Минушкин О.Н. Дисбактериоз кишечника: эволюция взглядов. Современные принципы диагностики и фармакологической коррекции. Consilium medicum. Приложение. Гастроэнтерология. 2006;2:4-18.
  22. Ghoshal U.C., Shulka R., Ghoshal U., et al. The Gut Microbiota and Irritable Bowel Syndrome: Friend or Foe? Quigley Int. J. Inflam. 2012; 151085.
  23. Morken M.H., Valeur J., Norin E., et al. Antibiotic or bacterial therapy in post-giardiasis irritable bowel syndrome. Scand. J. Gastroenterol. 2009;44(11):1296-303.
  24. Parodi A., Dulbecco P., Savarino E., et al. Positive glucose breath testing is more prevalent in patients with IBS-like symptoms compared with controls of similar age and gender distribution. J. Clin. Gastroenterol. 2009;43(10): 962-66.
  25. Messaoudi M., Violle N., Bisson J.F., et al. Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes. 2011;2(4):256-61.
  26. Skricka T., Hemmelova B., Mitas L., et al. Клостридиальный колит - важная проблема в хирургии. Пер. с англ. Д.Ю. Пикунов. Колопроктология. 2014;4:17-24.
  27. Конович Е.А., Халиф И.Л., Шапина М.В., et al. Дисбаланс циркулирующих цитокинов ИЛ-6 и ИЛ-10 у больных язвенным колитом. Колопроктология. 2014;4(50):35-40.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies